Quest Laboratories Ltd

As of 23-Jan, Quest Laboratories Ltd witnessed a sharp decline in its share price, falling by 9.2% to ₹96.20. This drop reflects a broader trend of underperformance relative to market benchmarks and recent operational challenges despite the company’s strong underlying fundamentals.

Quest Laborato has shown significant growth from Mar'23 to Mar'25, with net sales increasing from 0.62 Cr to 103.91 Cr and profit after tax rising from 0.05 Cr to 13.57 Cr, despite a negative cash flow of -23.00 Cr in Mar'25. Total assets also grew from 46.94 Cr to 121.65 Cr during this period.

As of 13-Nov, Quest Laboratories Ltd is seeing a price increase to 94.70, up 6.82% today, but has underperformed year-to-date with a decline of 21.77%. Despite recent gains, investor participation has notably decreased, raising concerns about future trading activity.

Quest Laborato has shown significant growth in net sales and profitability, with net sales rising from 0.62 Cr in Mar'23 to 103.91 Cr in Mar'25, and profit after tax increasing from 4.11 Cr to 13.57 Cr in the same period. However, the company faces challenges with negative cash flow from operating activities in Mar'25.

As of 06-Oct, Quest Laboratories Ltd's stock price is declining at 90.05, down 4.66%, and has underperformed its sector by 4.77%. Despite increased investor participation, the stock has dropped 25.61% year-to-date, contrasting sharply with the broader market's positive performance.

As of 24-Sep, Quest Laboratories Ltd's stock price is at 95.55, down 1.49%, and has underperformed its sector while trading below all key moving averages. The stock has seen an 80% drop in delivery volume and a year-to-date decline of 21.07%, indicating significant challenges for the company.

As of 23-Sep, Quest Laboratories Ltd is seeing a price increase to 97.00, up 1.09%, but has underperformed year-to-date with a decline of 19.87%. Despite a short-term gain, the stock faces challenges in maintaining investor confidence compared to the broader market.

As of 22-Sep, Quest Laboratories Ltd's stock price is 95.95, down 0.62%, with a significant decline in performance reflected in negative returns over the past week and month, and trading below all key moving averages. The stock has underperformed compared to the Sensex, which has gained, while Quest has seen a year-to-date decline of 20.74%.

As of 19-Sep, Quest Laboratories Ltd is facing a decline in its stock price, currently at 96.55, with a year-to-date drop of 20.24% and significant underperformance compared to the broader market. The stock is trading below all major moving averages and has seen a 35% decrease in investor participation.

As of 18-Sep, Quest Laboratories Ltd is priced at 97.00, down 0.05%. The stock has underperformed its sector and the broader market significantly, with a year-to-date decline of 19.87% despite increased investor participation.

As of 17-Sep, Quest Laboratories Ltd is seeing a price increase to 97.05, but has a year-to-date decline of 19.83%. Despite today's positive movement, the stock is underperforming compared to the market and trading below its moving averages, indicating potential bearish trends.

As of September 16, 2025, Quest Laboratories is considered very attractive and undervalued with a PE ratio of 11.35 and strong financial metrics, despite a year-to-date stock decline of 21.27% compared to a 6.74% gain in the Sensex.

As of 16-Sep, Quest Laboratories Ltd's stock price is declining at 95.30, down 1.75%, and has underperformed its sector by 2.03%. Despite a year-to-date drop of 21.27%, investor participation has increased, with delivery volume up 101.3% against the 5-day average.

As of September 15, 2025, Quest Laboratories is fairly valued with a PE ratio of 11.89 and an EV to EBITDA of 10.44, outperforming expensive peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -19.87% compared to the Sensex's 6.02%.